These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 32563285

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mestre TA, Lang AE, Okun MS.
    Mov Disord; 2016 Mar; 31(3):290-6. PubMed ID: 26952118
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature.
    Zis P, Mitsikostas DD.
    Int Rev Neurobiol; 2018 Mar; 139():443-462. PubMed ID: 30146057
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Placebo responses in Parkinson's disease.
    Lou JS.
    Int Rev Neurobiol; 2020 Mar; 153():187-211. PubMed ID: 32563288
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mestre TA, Shamy M, Benedetti F, Lang AE.
    Mov Disord; 2018 Aug; 33(8):1195-1203. PubMed ID: 30145820
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nocebo Effects: Neurobiological Mechanisms and Strategies for Prevention and Optimizing Treatment.
    Kleine-Borgmann J, Bingel U.
    Int Rev Neurobiol; 2018 Aug; 138():271-283. PubMed ID: 29681330
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The nocebo effect and its relevance for clinical practice.
    Colloca L, Miller FG.
    Psychosom Med; 2011 Sep; 73(7):598-603. PubMed ID: 21862825
    [Abstract] [Full Text] [Related]

  • 14. Nocebo and the contribution of psychosocial factors to the generation of pain.
    Benedetti F, Frisaldi E, Barbiani D, Camerone E, Shaibani A.
    J Neural Transm (Vienna); 2020 Apr; 127(4):687-696. PubMed ID: 31758266
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?
    Vase L.
    Scand J Pain; 2020 Jul 28; 20(3):451-467. PubMed ID: 32609651
    [Abstract] [Full Text] [Related]

  • 17. [Nocebo, informed consent and doctor-patient communication].
    Hansen E, Zech N, Benson S.
    Nervenarzt; 2020 Aug 28; 91(8):691-699. PubMed ID: 32728796
    [Abstract] [Full Text] [Related]

  • 18. What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain.
    Hughes J, Greville-Harris M, Graham CA, Lewith G, White P, Bishop FL.
    J Med Ethics; 2017 Dec 28; 43(12):867-870. PubMed ID: 28663259
    [Abstract] [Full Text] [Related]

  • 19. How the number of learning trials affects placebo and nocebo responses.
    Colloca L, Petrovic P, Wager TD, Ingvar M, Benedetti F.
    Pain; 2010 Nov 28; 151(2):430-439. PubMed ID: 20817355
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.